Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition

ABSTRACT Tumour antigen-induced inhibition of leucocyte adherence was modified for use in glass test tubes (Tube LAI assay) for the study of cell-mediated anti-tumour immunity to human

malignant melanoma. Peripheral blood leucocytes (PBL) of 20 out of 25 patients (80%) with active malignant melanoma responded to an extract of malignant melanoma with LAI, whereas only 4-5%

of 475 control subjects showed a response. The malignant melanoma patients reacted to both allogeneic and autologous extracts of malignant melanoma which indicates a common cross-reacting

antigen. Malignant melanoma patients did not respond to unrelated tumour extracts. The LAI was mediated by PBL (monocytes) "armed" with cytophilic anti-tumour antibody specific for

the sensitizing tumour antigen. The anti-tumour response of the malignant melanoma patients was dependent on the stage of the cancer, and 11 out of 13 Stage I patients had a positive NAI,

whereas patients with disseminated cancer had decreased response. The diminished LAI in patients with large tumour burdens appeared to be the result of release of tumour antigen

systemically. Also, surgery and chemotherapy depressed LAI. Although LAI was depressed after surgical excision of the cutaneous melanoma, most patients showed LAI 1-3 months later.

Tumour-free melanoma patients monitored for one year by the Tube LAI assay showed a decline in their anti-tumour immunity 5-6 months after surgery. The NAI was low or negative after the 8th

post-surgical month in tumour-free patients. Patients with residual malignant melanoma showed persistent or recurrent LAI after the 8th post-surgical month. LAI reactivity monitored after

"curative" surgery for malignant melanoma may assist in determining whether the patient is tumour-free or has a recurrence. Access through your institution Buy or subscribe This is

a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per

year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS DIRECT

ADMINISTRATION OF HUMAN LEUCOCYTE ANTIGEN (DHLA) MOLECULES INTO TUMOUR SITES: PROPOSAL FOR A NEW IMMUNOTHERAPY FOR CANCER Article Open access 23 October 2023 NEUTROPHILS BEARING ADHESIVE

POLYMER MICROPATCHES AS A DRUG-FREE CANCER IMMUNOTHERAPY Article 29 February 2024 A NON-HUMAN PRIMATE IN VITRO FUNCTIONAL ASSAY FOR THE EARLY EVALUATION OF TB VACCINE CANDIDATES Article Open

access 04 January 2021 Authors * J H Marti View author publications You can also search for this author inPubMed Google Scholar * D M Thomson View author publications You can also search

for this author inPubMed Google Scholar ADDITIONAL INFORMATION This worlk was supported by the Medical Research Council of Canada. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Marti, J., Thomson, D. Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition. _Br J Cancer_ 34, 116–133 (1976).

https://doi.org/10.1038/bjc.1976.134 Download citation * Issue Date: 01 August 1976 * DOI: https://doi.org/10.1038/bjc.1976.134 SHARE THIS ARTICLE Anyone you share the following link with

will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative